


10/30/01
J1044 U.S. PTO

12-04-01

A

Please type a plus sign (+) inside this box ☐

Attorney Docket **P1381R1C1P4**
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Jian Chen,
Ellen Filvaroff
Sherman Fong
Dorothy French
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Kenneth J. Hillan
Sarah G. Hymowitz
Hanzhong Li
James Pan
Melissa A. Starovasnik
Daniel Tumas
Menno Van Lookeren
Richard Vandlen
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Daniel G. Yansura

Title: **IL-17 Homologous Polypeptides and Therapeutic Uses Thereof**

JC858 U.S. PTO
10/000157
10/30/01

10000157 103001

1. Type of Application

☐ This application is for an original, non-provisional application.

☐ This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by reference.

☒ This is a continuation-in-part application which claims priority to U.S. Provisional Application Nos.: 60/253,646 filed November 28, 2000; 60/244,072 filed October 26, 2000; 60/242,837 filed October 24, 2000; 60/213,807 filed June 22, 2000; 60/191,007 filed March 21, 2000, now abandoned; 60/175,481 filed January 11, 2000, now abandoned; 60/172,096 filed December 23, 1999, now abandoned; 60/138,387 filed June 9, 1999, now abandoned; 60/134,287 filed May 14, 1999, now abandoned; 60/131,022 filed April 26, 1999, now abandoned; 60/130,232 filed April 21, 1999, now abandoned; 60/113,621 filed December 23, 1998, now abandoned; 60/085,579 filed May 15, 1998, now abandoned; and to which U.S. Provisional Applications claim priority under 35 U.S.C. §119; and also claims priority to International PCT Application Nos.: PCT/US01/21735 filed July 9, 2001; PCT/US01/21066 filed June 29, 2001; PCT/US01/19692 filed June 20, 2001; PCT/US01/17800 filed June 1, 2001; PCT/US01/06520 filed February 28, 2001; PCT/US00/34956 filed December 20, 2000; PCT/US00/32678 filed December 1, 2000; PCT/US00/30873 filed November 10, 2000; PCT/US00/23328 filed August 24, 2000; PCT/US00/15264 filed June 2, 2000; PCT/US00/07532 filed March 21, 2000; PCT/US00/05841 filed March 2, 2000; PCT/US00/05601 filed March 1, 2000; PCT/US00/04341 filed February 18, 2000; PCT/US99/31274 filed December 30, 1999; PCT/US99/10733 filed May 14, 1999; PCT/US99/05028 filed March 8, 1999; to which International PCT Applications claim priority under 35 U.S.C. §120; and also claims priority to U.S. Patent Application Nos.: 09/931,836 filed August 16, 2001; 09/929,404 filed August 13, 2001; 09/918,585 filed July 30, 2001; 09/908,827 filed July 18, 2001; 09/874,503 filed June 5, 2001; 09/854,280 filed May 10, 2001; 09/854,208 filed May 10, 2001; 09/816,744 filed March 22, 2001; 09/747,259 filed December 20, 2000; 09/644,848 filed August 22, 2000; 09/380,142 filed August 25, 1999; 09/380,138 filed August 25, 1999; 09/311,832 filed May 14, 1999; to which U.S. Patent Applications claim priority under 35 U.S.C. §120., the entire disclosures of which hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

159 pages of specification

9 pages of claims

1 page of abstract

70 sheet(s) of drawings

☐ formal ☒ informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

x An unsigned declaration of the inventors is enclosed. An executed declaration of the inventors will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

 A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

T0000157-103001

(for Cont./Div. where inventor(s) being deleted)

- ___ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

- x An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [x] will follow.

(for cont./div.)

- ___ The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

- ___ Cancel in this application original claims ___ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

- ___ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

- ___ Amend the specification by inserting before the first line the sentence:

--This is a

- ___ non-provisional application
___ continuation
___ divisional
___ continuation-in-part

of co-pending application(s)

- ___ Serial No. _ filed on __, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --
___ International Application _ filed on __ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--
___ provisional application No. _ filed __, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$740.00
Total Claims	60	- 20 =	40	X \$18.00	\$720.00
Independent Claims	28	- 3 =	25	X \$80.00	\$2,000.00
<u>X</u> Multiple dependent claim(s), if any				+ \$270.00	\$270.00
Filing Fee Calculation					\$3,730.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$3,730.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- _____ A copy of the petition for extension of time in the **prior** application is attached.

T00001 4510000

